Cost-Effectiveness Analysis of Regorafenib for Third-Line Metastatic Colorectal Cancer (MCRC) Compared to Cetuximab Plus Irinotecan in China
May 1, 2018, 00:00
10.1016/j.jval.2018.04.215
https://www.valueinhealthjournal.com/article/S1098-3015(18)30515-1/fulltext
Title :
Cost-Effectiveness Analysis of Regorafenib for Third-Line Metastatic Colorectal Cancer (MCRC) Compared to Cetuximab Plus Irinotecan in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30515-1&doi=10.1016/j.jval.2018.04.215
First page :
Section Title :
Open access? :
No
Section Order :
1061